Physician profile
Danny Ortiz
NPI 1780892695
$1,718.07
in general payments reported to CMS, 2019-2025
20 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $135 · 2023: $248 · 2024: $607 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $219.33 | 2023-2025 | |
| Exact Sciences Corporation | $179.77 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $167.53 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $160.05 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $140.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $137.86 | 2021-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $108.07 | 2022-2025 | |
| Abbvie INC. | $105.90 | 2021-2024 | |
| Dynavax Technologies Corporation | $95.05 | 2024-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $93.12 | 2024-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.79 | 2021-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $51.05 | 2021-2025 | Pifeltro |
| Medtronic, INC. | $48.14 | 2024-2025 | Intellis Adaptivestim |
| Nevro Corp. | $22.48 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.46 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.01 | 2023 | Veozah |
| Phadia US INC. | $18.60 | 2022 | |
| Stimwave Technologies Incorporated | $17.28 | 2021 | |
| Shield Therapeutics INC | $15.42 | 2024 | |
| Amarin Pharma, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.